XENT - Guggenheim softens view on four biotechs in premarket analyst action August, 02 2019 07:17 AM Intersect ENT Inc. Stericycle (NASDAQ:SRCL) upgraded to Neutral with a $44 (flat) price target at Baird.More news on: Stericycle, Inc., Abiomed, Inc., Adaptimmune Therapeutics plc, Healthcare stocks news, Stocks on the move, , Read more ...